Shah et al, AJKD, "Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study"

Table S1: Change in the area under the curve (AUC) for probable MI, all-cause mortality and the composite of MI / all-cause mortality with addition of plasma CX3CL1 data

	Without CX3CL1	With CX3CL1	P-value
Probable MI	0.66	0.67	0.01
All-cause mortality	0.68	0.7	< 0.001
MI or All-cause mortality	0.66	0.68	<0.001
ROC AUC in Model	5		
	Without CX3CL1	With CX3CL1	P-value
Probable MI	0.74	0.74	0.2
All-cause mortality	0.74	0.76	< 0.001
MI or All-cause mortality	0.73	0.74	0.01

Model 2: CX3CL1 + Demographic factors + Traditional risk factors (diabetes, hypertension, hyperlipidemia, tobacco use, body mass index)

Model 5: CX3CL1 + Demographic factors + Traditional risk factors + plasma inflammatory biomarkers + kidney function measures (CRIC-defined estimated glomerular filtration rate(14) and log transformed urinary albumin: creatinine ratio) + metabolic syndrome